Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis

Video

In Partnership With:

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis. 

Ruben A. Mesa, MD, director of the Mays Cancer Center at the University of Texas Health San Antonio MD Anderson Cancer Center, discusses the emergence of JAK inhibitors in myelofibrosis. 

Initially, JAK inhibitors were tested in patients with poor prognosis, explains Mesa.

Now, 2 JAK inhibitors, ruxolitinib (Jakafi) and fedratinib (Inrebic)​, are approv​ed for the treatment of patients with myelofibrosis. Notably, ruxolitinib is a JAK1/2 inhibitor, whereas fedratinib specifically ​inhibits JAK2. 

JAK inhibitors are increasingly being used in early-stage disease, wherein they are showing equal value in mitigating disease-related symptoms, Mesa concludes. 

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute